Explore the vast range of titles available.

\"A one-of-a-kind treasury of the most strange and fascinating knowledge and lore about animals. Largo tells us their most fascinating secrets and reveals fact after astonishing--and often hilarious--fact about their oddest behavior. Largo also looks at the beasts we created with our imaginations, as well as ones long gone\"-- Provided by publisher.

[...]there are as many as 14,500 different bamboo species and although we associate it with tropical climates some are exceptionally hardy and can even withstand freezing temperatures. The Bible reveals that just before Jesus overturned the moneychangers' tables in the Holy Temple of Jerusalem he arrived in the ancient city bearing an olive branch.

\"David Attenborough meets Lemony Snicket in The Big Bad Book of Botany, Michael Largo's entertaining and enlightening one-of-a-kind compendium of the world's most amazing and bizarre plants, their history, and their lore. The Big, Bad Book of Botany introduces a world of wild, wonderful, and weird plants. Some are so rare, they were once more valuable than gold. Some found in ancient mythology hold magical abilities, including the power to turn a person to stone. Others have been used by assassins to kill kings, and sorcerers to revive the dead. Here, too, is vegetation with astonishing properties to cure and heal, many of which have long since been lost with the advent of modern medicine. Organized alphabetically, The Big, Bad Book of Botany combines the latest in biological information with bizarre facts about the plant kingdom's oddest members, including a species that is more poisonous than a cobra and a prehistoric plant that actually 'walked.' Largo takes you through the history of vegetables and fruits and their astonishing agricultural evolution. Throughout, he reveals a astonishing facts, from where the world's first tree grew to whether plants are telepathic. Featuring more than 150 photographs and illustrations, The Big, Bad Book of Botany is a fascinating, fun A-to-Z encyclopedia for all ages that will transform the way we look at the natural world.\"--from publisher's description.

Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain to be developed. We aimed to assess whether 6-month treatment with abatacept improves inflammation in preclinical rheumatoid arthritis. The abatacept reversing subclinical inflammation as measured by MRI in ACPA positive arthralgia (ARIAA) study is a randomised, international, multicentre, double-blind, placebo-controlled trial done in 14 hospitals and community centres across Europe (11 in Germany, two in Spain, and one in the Czech Republic). Adults (aged ≥18 years) with ACPA positivity, joint pain (but no swelling), and signs of osteitis, synovitis, or tenosynovitis in hand MRI were randomly assigned (1:1) to weekly subcutaneous abatacept 125 mg or placebo for 6 months followed by a double-blind, drug-free, observation phase for 12 months. The primary outcome was the proportion of participants with any reduction in inflammatory MRI lesions at 6 months. The primary efficacy analysis was done in the modified intention-to-treat population, which included participants who were randomly assigned and received study medication. Safety analyses were conducted in participants who received the study medication and had at least one post-baseline observation. The study was registered with the EUDRA-CT (2014–000555–93). Between Nov 6, 2014, and June 15, 2021, 139 participants were screened. Of 100 participants, 50 were randomly assigned to abatacept 125 mg and 50 to placebo. Two participants (one from each group) were excluded due to administration failure or refusing treatment; thus, 98 were included in the modified intention-to-treat population. 70 (71%) of 98 participants were female and 28 (29%) of 98 were male. At 6 months, 28 (57%) of 49 participants in the abatacept group and 15 (31%) of 49 participants in the placebo group showed improvement in MRI subclinical inflammation (absolute difference 26·5%, 95% CI 5·9–45·6; p=0·014). Four (8%) of 49 participants in the abatacept group and 17 (35%) of 49 participants in the placebo group developed rheumatoid arthritis (hazard ratio [HR] 0·14 [0·04–0·47]; p=0·0016). Improvement of MRI inflammation (25 [51%] of 49 participants in the abatacept group, 12 [24%] of 49 in the placebo group; p=0·012) and progression to rheumatoid arthritis (17 [35%] of 49, 28 [57%] of 49; HR 0·14 [0·04–0·47]; p=0·018) remained significantly different between the two groups after 18 months, 12 months after the end of the intervention. There were 12 serious adverse events in 11 participants (four [8%] of 48 in the abatacept group and 7 [14%] of 49 in the placebo group). No deaths occurred during the study. 6-month treatment with abatacept decreases MRI inflammation, clinical symptoms, and risk of rheumatoid arthritis development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase. Innovative Medicine Initiative.

Background: This technical note presents a methodological approach to agrichemical inventory documentation. It complements exposure assessments in field settings with time-restricted observational periods. Conducted in Michoacán, Mexico, this method leverages large language model (LLM) capabilities for categorizing agrichemicals from brief video footage. Method: Given time-limited access to a storage shed housing various agrichemicals, a short video was recorded and processed into 31 screenshots. Using OpenAI’s ChatGPT (model: GPT-4o®), agrichemicals in each image were identified and categorized as fertilizers, herbicides, insecticides, fungicides, or other substances. Results: Human validation revealed that the LLM accurately identified 75% of agrichemicals, with human verification correcting entries. Conclusions: This rapid identification method builds upon behavioral methods of exposure assessment, facilitating initial data collection in contexts where researcher access to hazardous materials may be time limited and would benefit from the efficiency and cross-validation offered by this method. Further refinement of this LLM-assisted approach could optimize accuracy in the identification of agrichemical products and expand its application to complement exposure assessments in field-based research, particularly as LLM technologies rapidly evolve. Most importantly, this Technical Note illustrates how field researchers can strategically harness LLMs under real-world time constraints, opening new possibilities for rapid observational approaches to exposure assessment.

Extracellular deposition of amyloid β-protein (Aβ) in amyloid plaques and intracellular accumulation of abnormally phosphorylated τ-protein (p-τ) in neurofibrillary tangles (NFTs) represent pathological hallmark lesions of Alzheimer’s disease (AD). Both lesions develop in parallel in the human brain throughout the preclinical and clinical course of AD. Nevertheless, it is not yet clear whether there is a direct link between Aβ and τ pathology or whether other proteins are involved in this process. To address this question, we crossed amyloid precursor protein (APP) transgenic mice overexpressing human APP with the Swedish mutation (670/671 KM → NL) (APP23), human wild-type APP (APP51/16), or a proenkephalin signal peptide linked to human Aβ42 (APP48) with τ-transgenic mice overexpressing human mutant 4-repeat τ-protein with the P301S mutation (TAU58). In 6-month-old APP23xTAU58 and APP51/16xTAU58 mice, soluble Aβ was associated with the aggravation of p-τ pathology propagation into the CA1/subiculum region, whereas 6-month-old TAU58 and APP48xTAU58 mice neither exhibited significant amounts of p-τ pathology in the CA1/subiculum region nor displayed significant levels of soluble Aβ in the forebrain. In APP23xTAU58 and APP51/16xTAU58 mice showing an acceleration of p-τ propagation, Aβ and p-τ were co-immunoprecipitated with cellular prion protein (PrPC). A similar interaction between PrPC, p-τ and Aβ was observed in human AD brains. This association was particularly noticed in 60% of the symptomatic AD cases in our sample, suggesting that PrPC may play a role in the progression of AD pathology. An in vitro pull-down assay confirmed that PrPC is capable of interacting with Aβ and p-τ. Using a proximity ligation assay, we could demonstrate proximity (less than ~ 30–40 nm distance) between PrPC and Aβ and between PrPC and p-τ in APP23xTAU58 mouse brain as well as in human AD brain. Proximity between PrPC and p-τ was also seen in APP51/16xTAU58, APP48xTAU58, and TAU58 mice. Based on these findings, it is tempting to speculate that PrPC is a critical player in the interplay between Aβ and p-τ propagation at least in a large group of AD cases. Preexisting p-τ pathology interacting with PrPC, thereby, appears to be a prerequisite for Aβ to function as a p-τ pathology accelerator via PrPC.

''If they've been secretive in the past, they'll be secretive as president,'' Mr. [Barack Obama] told voters in Mason City. ''If they haven't been all that strong on lobbyists in the past, it doesn't matter what they say during the campaign, they won't be that strong about it when they're president.'' ''It's not going to be easy, this job never is; it's the hardest job in the world,'' she said. ''On Jan. 20, 2009, someone will raise his or her hand to take the oath of office in front of our Capitol. And then that person will go to the Oval Office. And on the desk in the Oval Office will be a stack of problems.'' David Axelrod, a senior adviser to Mr. Obama, disputed that. ''I think we may have a broader reach than [John Edwards],'' Mr. Axelrod said. ''We're bringing in a lot of new people.''

Nationally, death rates from prescription opioid pain reliever (OPR) overdoses quadrupled during 1999-2010, whereas rates from heroin overdoses increased by <50%. Individual states and cities have reported substantial increases in deaths from heroin overdose since 2010. CDC analyzed recent mortality data from 28 states to determine the scope of the heroin overdose death increase and to determine whether increases were associated with changes in OPR overdose death rates since 2010. This report summarizes the results of that analysis, which found that, from 2010 to 2012, the death rate from heroin overdose for the 28 states increased from 1.0 to 2.1 per 100,000, whereas the death rate from OPR overdose declined from 6.0 per 100,000 in 2010 to 5.6 per 100,000 in 2012. Heroin overdose death rates increased significantly for both sexes, all age groups, all census regions, and all racial/ethnic groups other than American Indians/Alaska Natives. OPR overdose mortality declined significantly among males, persons aged <45 years, persons in the South, and non-Hispanic whites. Five states had increases in the OPR death rate, seven states had decreases, and 16 states had no change. Of the 18 states with statistically reliable heroin overdose death rates (i.e., rates based on at least 20 deaths), 15 states reported increases. Decreases in OPR death rates were not associated with increases in heroin death rates. The findings indicate a need for intensified prevention efforts aimed at reducing overdose deaths from all types of opioids while recognizing the demographic differences between the heroin and OPR-using populations. Efforts to prevent expansion of the number of OPR users who might use heroin when it is available should continue.

The smaller volume of the profunda artery perforator (PAP) flap relative to that of abdominal flaps limits the size of breast reconstruction that may be achieved. Immediate implant augmentation of abdominal free flaps has been performed, but immediate implant augmentation of PAP flaps has never been described. A 54-year-old woman with BRCA2 mutation, submuscular implants, and previous abdominoplasty presented for nipple-sparing mastectomies (NSM). Autologous tissue volume was inadequate to support reconstruction to the desired size. She wished to avoid serial expansion. Skin quality was unsuitable for direct-to-implant reconstruction. The patient underwent bilateral NSM. The previous implants were removed with capsule preservation. Bilateral PAP flaps were harvested and anastomosed to the internal mammary vessels. Moderate classic profile 170-mL smooth round silicone implants were placed into the existing capsule pockets with lateral capsulorraphy. There were no flap, implant, or infectious complications. Initial mastectomy skin and nipple ischemia completely resolved without necrosis. Donor site healing was uneventful. At 8 months, the reconstruction is supple and the implants remain well-positioned without rippling. One minor revision was performed for fat grafting and to correct lateral nipple deviation. PAP flap breast reconstruction with immediate implant augmentation is technically feasible. Advantages include improved prosthetic coverage, allowing for immediate reconstruction to a larger size with reduced concern regarding mastectomy skin necrosis and threat to the device, optimal implant camouflage, and improved substrate for secondary fat grafting if necessary. Level of Evidence: 5

Objective: To study the relationships among perceived problem solving, stress, and physical health. Methods: The Perceived Stress Questionnaire (PSQ), Personal Problem solving Inventory (PSI), and a stress-related physical health symptoms checklist were used to measure perceived stress, problem solving, and health among undergraduate college students (N=232). Results: Perceived problem-solving ability predicted self-reported physical health symptoms (R2 = .12; P < .001) and perceived stress (R2 = .19; P < .001). Conclusion: Perceived problem solving was a stronger predictor of physical health and perceived stress than were physical activity, alcohol consumption, or social support. Implications for college health promotion are discussed.